|
|
|
CANCER AND LYMPHOMA GENETICS MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner Bond GL, Hirshfield KM, KirchhoffT, Alexe G, Bond EE, Robins H, Basrtel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ.. Cancer Research 2006,66(10):5104-10 Accuracy of BRCAI and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue Adank MA, Brogi E, Bogomolniy F, Wadsworth EA, Lafaro KJ, Yee CJ, KirchhoffT, Meijers-Heijboer EJ, KauffNK, Boyd J, Offit K.. Familial Cancer 2006 (in press) Cancer Genetic Testing and Assisted Reproduction. Offit K, Kohut K, Clagett B, Wadsworth E, Cummings S, White M, Sagi M, Bernstein D, Davis JG. Journal of Clinical Oncology 2006. Electronically published online by the Journal of Clinical Oncology in July, 2006 and was formally published in October 2006
2004-2005 The TP53 Mutational spectrum and frequency of CHEK2* 1100delC in Li Fraumeni-like kindreds Siddiqui, R, Onel K, Facio F, Nafa D, Robles-Diaz R, Kauff N, Huang H, Robson M, Ellis N, Offit K Familial Cancer 2005; 4(2):177-81 Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, Offit K, Pasche B. Cancer Research 2005; 65(8):3454-61. Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang H, Chen M, Lippert R, Halldorsson BV, Woodworth B, White T, Clark AG, Parl FF, Broder S, Dean M, Offit K. Cancer Research 2004; 64:8891-900.
Localization of cancer susceptibility genes by genome-wide
single-nucleotide polymorphism linkage-disequilibrium mapping.
Mitra N, Ye
TZ, Smith A, Chuai S, Kirchhoff T, Peterlongo P, Nafa K, Phillips MS,
Offit K, Ellis NA.
Cancer Research
2004; 64: 8116-25. |
|
Hereditary ovarian cancer in Ashkenazi Jews. Robles-Diaz L, Goldfrank D, Kauff N, Robson M, Offit K Familial Cancer 2004; 3:259-64
A636P testing in Ashkenazi Jews. Guillem JG, Moore HG, Palmer, C, Glogowski E,
Finch R, Nafa K, Markowitz AJ, Pleomorphic expression of a germline kit mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Robson ME, Glogowski E, Sommer G, Antonescu CR, Khedoudja N, Maki RG, Ellis N, Besmer P, Brennan M, Offit K. Clinical Cancer Research 2004;10:1250-4.
Functional and
genomic approaches reveal an ancient CHEK2 allele associated with breast
cancer in the Ashkenazi Jewish population.
Shaag A, Walsh T,
Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee
MK, Ellis N, Offit K, Levy-Lahad E, King MC. Human Molecular Genetics
2005; 14:555-63 |
|
2002-2003 Analysis of Mismatch Repair Defects in the Familial Occurrence of Lymphoma and Colorectal Cancer, Teruya-Feldstein, J., Greene, J., Cohen, L., Popplewell, L., Ellis, N.A., Offit, K., Leukemia and Lymphoma, 2002 Vol. 43 (8), pp. 1619-1626.
|
|
2002-2005 Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, Offit K, Pasche B. Cancer Research 2005; 65(8):3454-61. Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang H, Chen M, Lippert R, Halldorsson BV, Woodworth B, White T, Clark AG, Parl FF, Broder S, Dean M, Offit K. Cancer Research 2004; 64:8891-900. Hereditary ovarian cancer in Ashkenazi Jews. Robles-Diaz L, Goldfrank D, Kauff N, Robson M, Offit K Familial Cancer 2004; 3:259-64 Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Shaag A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee MK, Ellis N, Offit K, Levy-Lahad E, King MC. Human Molecular Genetics 2005; 14:555-63
Localization of Breast Cancer
Susceptibility Loci by Genome-Wide SNP Linkage Disequilibrium Mapping,
N.A. Ellis, T. Kirchhoff, N. Mitra,
T.-Z. Ye, S. Chuai, H. Huang, K. Nafa, L. Norton, S. Neuhausen, J.P.
Struewing, S. Narod, K. Offit, (in preparation).
Risk-Reducing Salpingo-Oophorectomy in Women with a BRCA1 or BRCA2
Mutation,
Kauff, N.D., Satagopan, J.M., Robson, M.E., Scheuer, L., Hensley, M.,
Hudis, C.A., Ellis, N.A., Boyd, J., Borgen, P.I., Barakat, R.R., Norton,
L., Offit, K., N Engl J Med, Vol. 346 , No. 21 May 23, 2002:
pp 1609-1615. Frequency of CHEK2*1100delC in New York breast cancer cases and controls, K. Offit, H. Pierce, T. Kirchhoff, P. Kolachana, B. Rapaport, P. Gregersen, S. Johnson, O. Yossepowitch, H. Huang, J. Satagopan, M. Robson, L. Scheuer, BMC Medical Genetics, 2003, 4, http://www.biomedcentral.com/1471-2350/4/1.
BRCA1 AND BRCA2 Germline Mutations in Lymphoma Patients, O. Yossepowitch, N. Olvera, J. M. Satagopan, H. Huang, S. Jhanwar, B. Rapaport, J. J. Boyd, K. Offit, Leukemia and Lymphoma, 2003 Vol. 44 (1), pp. 127-131 COLON CANCER and OTHER GASTROINTESTINAL GENETICS
2004
2002-2003
2004-2005 The TP53 Mutational spectrum and frequency of CHEK2* 1100delC in Li Fraumeni-like kindreds Siddiqui, R, Onel K, Facio F, Nafa D, Robles-Diaz R, Kauff N, Huang H, Robson M, Ellis N, Offit K Familial Cancer 2005; 4(2):177-81 The FANCD1/BRCA2*6174DELT Mutation is Rare in Sporadic Pediatric Medulloblastoma, K. Onel, T. Kirchhoff, J.C. Allen, E. Jiminez, K. Offit, (in preparation)
**Dr. Kenneth Offit
is
the Director of the Clinical Genetics
Service at the Memorial Sloan Kettering Cancer Center and author of
Clinical Cancer Genetics
|
|
YOUR CONTRIBUTIONS PLAY AN IMPORTANT PART IN MOVING BASIC RESEARCH FROM THE LABORATORY TO THE BEDSIDE
|
|
or you can return to review other CLINICIAN SCIENTISTS SUPPORTED BY LYMPHOMA FOUNDATION GRANTS or return to the PUBLICATION PAGE |
|
▲HOME ▲SCIENTISTS ▲RESEARCH ▲ EVENTS ▲ BOARD ▲ FELLOWS ▲BREAST CANCER ▼PUBLICATIONS
The Lymphoma Foundation is a nationwide not for profit foundation dedicated to funding clinical and basic laboratory cancer research and applying the knowledge developed by the clinician scientists to the general welfare and education of all cancer patients. © Copyright 2006 THE LYMPHOMA FOUNDATION All rights reserved |
